Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apl-1202 + bacillus calmette-guerin
- Development stage
- Unknown
- Lead developer
- Asieris Pharmaceuticals
- Modality
- Small Molecules, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral (APL-1202), Intravesical (bcg)
01
Overview
**APL-1202 + bacillus calmette-guerin** is a combination therapy investigated for **recurrent non-muscle invasive bladder cancer (NMIBC)**. **APL-1202** is an orally available small molecule inhibitor of methionine aminopeptidase 2 (**MetAP2**), possessing anti-angiogenic and anti-tumor properties. **Bacillus Calmette-Guerin** (BCG) is a live attenuated strain of *Mycobacterium bovis* administered intravesically as an immunotherapy to stimulate local immune responses against bladder cancer cells. This combination aims to enhance treatment outcomes in NMIBC by leveraging APL-1202's anti-tumor effects with BCG's established immune activation mechanisms[1][9]. - APL-1202 is being developed primarily by Asieris Pharmaceuticals. - BCG works chiefly by activating immune responses (involving T cells, NK cells, mast cells, and granulocytes), leading to anti-tumor activity in the bladder[2][4]. - The combination is administered as oral APL-1202 alongside intravesical BCG instillation[1][4]. - The therapy is in clinical trials for recurrent NMIBC.
- Other names
- nitroxoline + bacillus calmette-guerinMetAP2 inhibitor + BCG
02
Targets
PRR (Pattern recognition receptors)METAP2 (Methionine aminopeptidase 2)
Beyond the preview
Go deeper on apl-1202 + bacillus calmette-guerin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apl-1202 + bacillus calmette-guerin.